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Objectives: For patients undergoing lung resection for cancer, macroscopic evi-
dence of metastasis is clearly associated with adverse prognosis. However, less is
known about the significance of tumor cells detected by using tests such as pleural
lavage cytology. To ascertain the frequency and quantify the effect of this finding
on survival, we performed a prospective study of intraoperative pleural lavage
cytology.
Methods: Pleural lavage cytology consisted of cytologic analysis of 100 mL of
saline irrigated over the lung surface immediately after thoracotomy. Patients were
excluded if they had an existing effusion, extreme adhesions, or lateral chest wall
invasion or if resection was not performed. Survival was calculated by means of
Kaplan-Meier analysis and compared by using log-rank tests. Cox regression was
used to ascertain independent predictors of prognosis.
Results: From 1995 through 2003, we performed pleural lavage cytology on 292
patients undergoing thoracotomy for lung cancer. The mean age was 64 (SD, 10)
years, and 196 (67%) patients were men. Of 292 samples, 13 (4.5%) showed
evidence of malignant cells. The median time to follow-up was 15 months (inter-
quartile range, 1-40 months), with a median survival of 49 months for patients with
negative pleural lavage cytology results and 13 months for patients with positive
pleural lavage cytology results (P  .002). Univariate prognostic predictors were
positive pleural lavage cytology status (P  .03), stage (P  .03), adenocarcinoma
(P  .06), and parietal pleural involvement (P  .01). In the final multivariate
model only positive pleural lavage cytology status (P  .006) and stage (P  .03)
remained significant.
Conclusions: Intraoperative pleural lavage cytology is a simple addition to intratho-
racic staging and an independent predictor of prognosis. Positive results potentially
affect survival by upstaging patients to stage IIIB or greater.
Accurate and reproducible staging is the fundamental basis forpatient management, evaluation of research, and communicationin the treatment of lung cancer.1 Investigating for local, lym-phatic, and hematogenous invasion is part of the routine evalua-tion before lung resection. Although these staging methods tend toconcentrate on macroscopic evidence of disseminated disease,
advances in cytochemistry, immunohistochemistry, and polymerase chain reaction
techniques facilitate detection of micrometastatic disease.2 In patients without
evidence of metastasis, isolated tumor cells have been detected in the bone marrow
and lymph nodes, even though conventional stains have failed to detect such
disease.3,4
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Because these findings are becoming increasingly clini-
cally relevant, thoracic surgeons are now evaluating the
significance of tumor cells detected on washings of the
pleural cavity. The contribution to staging and the utility to
influence subsequent patient management are not clearly
defined.
In an attempt to ascertain the frequency of tumor cells on
pleural washings and to characterize the effect on prognosis,
we performed a prospective study of pleural lavage cytol-
ogy (PLC) in patients who had thoracotomy and lung re-
section for non–small cell lung cancer (NSCLC) at our
institution.
Methods
This study was conducted from 1995 through 2003, including all
patients with known or suspected NSCLC who had a thoracotomy
for intended surgical resection. Patients with a confirmed diagnosis
of NSCLC formed the population for this study, and we did not
include any patients with benign disease. We excluded patients
who had an existing effusion at the time of the operation (defined
as visible evidence of fluid in the pleural cavity), extreme adhe-
sions, or chest wall invasion or in whom resection was not per-
formed.
Preparation of the Sample
Immediately after thoracotomy but before any manipulation of the
tumor, 100 mL of normal saline was instilled into the pleural space
through a wide-bore catheter. The fluid was irrigated over the
visceral and parietal pleura, but forceful irrigation over the tumor
was avoided. The sample was then aspirated and placed in a sterile
container with 1 mL of 20% sodium citrate. The sample was mixed
by means of repeated inversion. Isolation of cells from erythro-
cytes was achieved by using a centrifugal sedimentation system.
Two 16-mL centrifuged tubes were prepared by layering 12 mL of
sample over 3 mL of Lymphoprep medium (Nycomed Pharma AS)
and centrifuging at 2000 rpm for 20 minutes. Cells were harvested
from the sample-medium interface with a Pasteur pipette and
resuspended in 2 mL of supernatant. Four cytologic slides of this
fraction were prepared by using a Cyto-Tek centrifuge (Bayer
Diagnostics), subsequently fixed in formal acetic alcohol, and
stained with the Papanicolaou technique. The slides were then
screened by a pathologist (AGN) for the presence of malignant
cells.
Data Acquisition
Individual patient data were collated from a prospective histopa-
thology database. Survival status was determined from the date of
last follow-up in a hospital outpatient or general practitioner’s
clinic. Mortality status was documented from patient records and
the NHS strategic tracing service.
Statistical Analysis
Patients were grouped according to the results of intraoperative
PLC. Categoric data are presented as frequency (in percentages)
and continuous data as means with SDs or medians with interquar-
tile ranges. Comparisons of categoric data between the 2 groups
were made by using 2 or Fisher exact tests. Continuous data were
compared by using 2-tailed t tests or Mann-Whitney tests as
appropriate to the distribution of the data.
Actuarial survival was estimated by using the Kaplan-Meier
method and compared with the log-rank test. Cox proportional
hazards regression was used to ascertain the individual contribu-
tion of factors associated with survival and to compare the risk-
adjusted survival between the 2 groups. The criterion for variable
retention was a P value of less than .1.
Results
From January 1, 1995, to January 1, 2003, a total of 292
PLC samples were received from patients who fulfilled the
inclusion criteria and underwent surgical resection for
NSCLC.
The mean age of the cohort was 64 (SD, 10) years, and
196 (67%) of the patients were men. Of 292 samples, 13
(4.5%) had evidence of malignant cells. Patients with pos-
itive PLC results were well matched for age and sex. How-
ever, more underwent pneumonectomy and had a higher
stage compared with patients who had negative PLC results.
In our series all patients with stage IV disease had M1 status
by virtue of a second tumor in a different lobe. The baseline
characteristics and stage are summarized in Tables 1 and 2,
respectively.
The median time to follow-up was 15 months (interquar-
tile range, 1-40 months), with a median survival of 49 (SE,
2.81) months for patients with negative PLC results and 13
(SE, 8.9) months for patients with positive PLC results (P
.002, Figure 1).
The univariate prognostic predictors were positive PLC
status (P  .03), stage (P  .03), adenocarcinoma (P 
.06), and parietal pleural involvement (P  .01), as sum-
marized in Table 3. During statistical modeling, PLC status
(P  .002) as a prognostic predictor was independent of N
stage (P  .001) and T stage (P  .9). In the final multi-
variate model, only positive PLC status (P  .006) and
overall stage (P  .03) were retained as independent prog-
nostic predictors (Table 4 and Figure 2).
A subanalysis of the 12 patients with positive PLC
results with stage IB to IIIB disease (after excluding one
patient with stage IV disease) compared with the 17 patients
with stage IIIB disease in the group with negative PLC
results suggested poorer survival when PLC results were
positive (P  .06, Figure 3).
Discussion
How common is intracoelomic disease in patients who
undergo lung resection without evidence of pleural effu-
sion? In our series the proportion was relatively low (4.5%).
However, reports in the literature range between 9% and
38%. The proportion of positive lavage results varies not
only with the patient population but also with the technique
of acquiring the sample. The volume of lavage fluid used to
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acquire a sample ranges from 50 to 1500 mL, and different
carrier solutions, such as saline and Ringer’s lactate have
been used.3,5-9 Generally, most samples have been acquired
immediately after thoracotomy and before surgical interven-
tion.3,6,8 However, some have performed PLC after surgical
intervention,10 and others have performed PLC both before
and after lung resection.5,7 Despite the inconsistencies in
volume, carrier solutions, timing of collection, and process-
ing, one finding has been consistent: a uniformly poor
prognosis in patients with positive results.
Role for PLC in Staging
Although some studies have identified positive PLC results
as an independent predictor of prognosis,6 not all studies
that report a poorer survival were able to confirm whether
this was independent of stage.3 This problem stems from
small numbers of patients with positive PLC results and the
variable effect on survival in each series. Our study supports
positive PLC results as a prognostic indicator that is inde-
pendent of overall stage and, in particular, nodal status.
Where and how PLC could be implemented into conven-
tional lung cancer staging is still unclear. It is recommended
that the cytologic results of pleural and peritoneal washings
be considered separate to the classification of isolated tumor
cells and micrometastasis. In addition, identification of pa-
tients with positive PLC results requires the suffix of (cy)
if this is to be the basis of classification of this subset to T4
disease (ie, T4 [cy]).11
In our series patients with positive PLC results had
equivalent or possibly poorer survival to that of patients
with stage IIIB disease (P  .06). This is despite having
83% (10/12) of such patients with stage IB to IIIA disease.
Clearly, positive PLC results have the effect of upstaging
patients to at least T4 status, a finding with prognostic
implications similar to those of a malignant effusion. Al-
though we did not have a group of patients with stage IV
disease to ascertain whether survival was comparable, the
median survival of 13 months is similar to that of patients
with stage IV disease reported by Naruke and colleagues.12
A Unique Problem
Currently, patients with stage IIIB and IV disease are gen-
erally (with few exceptions) considered to have inoperable
disease,13 and surgeons can justifiably choose not to pro-
ceed to lung resection when faced with unexpected stage
IIIB or IV disease in the operating theater. However, pa-
tients with positive PLC results belong to a small subgroup
TABLE 1. Baseline characteristics, operation extent, and cell type
PLC negative PLC positive P value
No. 279 13
Age, y (SD) 64 (11) 63 (7) .84
Male, n (%) 188 (67) 8 (62) .66
Operation
Pneumonectomy, n (%) 57 (20) 5 (38)
Lobectomy, n (%) 193 (69) 5 (38)
Bilobectomy, n (%) 15 (5) 1 (8) .03
Segmentectomy, n (%) 7 (2) 0 (0)
Nonanatomic resection, n (%) 7 (3) 2 (15)
Histology
Squamous, n (%) 114 (41) 2 (15)
Adenocarcinoma, n (%) 118 (42) 10 (77)
Large cell, n (%) 23 (8) 0 (0) .12
Mixed, n (%) 14 (5) 1 (8)
Other, n (%) 10 (4) 0 (0)
Visceral pleura involvement, n (%) 87 (31) 7 (54) .08
Parietal pleura involvement, n (%) 6 1 .21
TABLE 2. Staging characteristics
PLC negative PLC positive P value
No. 279 13
Stage
IA, n (%) 51 (18) 0 (0)
IB, n (%) 108 (39) 3 (23)
IIA, n (%) 12 (4) 1 (8)
IIB, n (%) 53 (19) 1 (8) .01
IIIA, n (%) 35 (13) 5 (38)
IIIB, n (%) 17 (6) 2 (15)
IV, n (%) 3 (1) 1 (8)
T category
T1, n (%) 74 (27) 3 (23)
T2, n (%) 181 (65) 8 (62)
T3, n (%) 8 (3) 0 (0) .51
T4, n (%) 16 (6) 2 (15)
N category
N0, n (%) 197 (71) 8 (62)
N1, n (%) 47 (17) 1 (8) .15
N2, n (%) 35 (13) 4 (31)
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with disease that is not detectable by means of conventional
staging methods and who might have surgically resectable
disease with a pathologic stage as early as IB (in our series).
Because we are unlikely to develop an infrastructure that is
quick enough to provide us the necessary information in-
traoperatively, the results of PLC are not available until
after the operation, compounding the problem of the man-
agement of these patients. Even if we did use preoperative
video-assisted thoracoscopy to obtain lavage fluid for PLC,
the cost and potential morbidity for a detection rate of 4.5%
would far outweigh the clinical utility of this investigation,
especially when we do not as yet have a clear management
plan for patients with positive results. With our present
knowledge, it would not be appropriate to turn down pa-
tients with potentially resectable disease in the absence of
further confirmatory studies.
Clinical Implications
Clearly the challenge is to define the optimal management
strategy for this small but important subset of patients. A
recent study of this subgroup by Ichinose and associates14
suggested reduced carcinomatous pleuritis in patients with
positive PLC results who had hypotonic cisplatin infused
into the pleural space after lung resection. However, the
study terminated prematurely before the effects on recur-
Figure 1. Overall survival by PLC status.
TABLE 3. Univariate predictors of survival
Variable Odds ratio P value
PLC 2.45 .03
Stage (.03)*
I 1.00
II 1.16 .29
III 1.23 .04
IV 1.01 .95
Age (per additional yr) 1.02 .12
Female sex 0.87 .28
Extent of resection
Pneumonectomy 1.00
Lobectomy 0.82 .17
Bilobectomy 0.91 .58
Segmentectomy 1.13 .63
Nonanatomic resection 0.86 .47
Histology
Squamous 1.00
Adenocarcinoma 1.31 .06
Large cell 1.18 .19
Mixed 0.99 .92
Other 0.35 .56
Maximum size (per additional mm) 0.99 .52
Visceral pleura involvement 0.88 .62
Parietal pleura involvement 10.33 .01
*The overall contribution of stage was assessed by using the likelihood
method.
TABLE 4. Multivariate predictors of survival
Variable Odds ratio P value
Positive PLC results 2.52 .006
Stage (.03)*
I 1.00
II 1.17 .21
III 1.23 .01
IV 1.07 .80
*The overall contribution of stage was assessed by using the likelihood
method.
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rence or mortality could be assessed. Realistically, until we
can accurately and consistently identify patients in this
subgroup, it would be difficult to evaluate the benefits of
any adjuvant therapy. Moreover, this is based on the as-
sumption that positive PLC results are an indicator of pleu-
ral extravasation of the primary tumor. It is equally con-
ceivable that positive PLC results occur as a result of
increasing metastatic potential and widespread microscopic
disease detected on pleural washings.
Potential Limitations
Like many other studies on this topic, the numbers of
patients with positive PLC results were small, limiting the
ability to make robust conclusions. However, our data are
clearly consistent with those of other reports as an adverse
prognostic indicator. Because of sample size constraints, we
were unable to ascertain with certainty whether visceral
pleural involvement was associated with positive PLC re-
sults, and we did not have information on disease recurrence.
Figure 2. Survival by PLC status adjusted for stage.
Figure 3. Survival comparing patients with stage IIIB disease with all patients with positive PLC results.
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Future Direction
PLC is a relatively inexpensive (approximate cost is £40,
US $65.45) and simple technique that identifies an impor-
tant subset of surgical candidates with poor prognosis. How-
ever, standardization of sample acquisition and preparation
is essential for widespread adoption and interpretation of
future studies. Although numerous studies have been pub-
lished on this topic, further studies or individual patient data
meta-analyses of published trials are required to facilitate
the accurate redefinition of a stage to this subgroup of
patients.
Conclusions
Intraoperative PLC is a simple and inexpensive technique
that identifies surgical patients with micrometastasis other-
wise undetectable by means of conventional staging meth-
ods. The information provided by PLC conveys important
additional prognostic information and potentially affects
survival by upstaging patients to stage IIIB or greater.
Standardization of sample acquisition and further studies
are required to define the exact stage of patients with pos-
itive PLC results before it becomes widely adopted for
staging. Further information on relapse patterns is needed
before the prognostic information obtained can be used to
assess the effect of adjuvant therapy.
We gratefully acknowledge the contribution of Christopher
Jackson, PhD, for his assistance with the statistical analysis for this
study.
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